Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 1

Submit an article Journal homepage

Free access

1,492

Views

CrossRef citations to date

Altmetric

Reviews

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

E VrdoljakUniversity Hospital Split, Department of Oncology, Split, CroatiaCorrespondence[email protected]

L TordayUniversity of Szeged, Department of Oncotherapy, Szeged, Hungary

C SzczylikCentral Clinical Hospital, Department of Oncology, Military Institute of Medicine, Warsaw, Poland

G KharkevichNN Blokhin Russian Cancer Research Center, Biotherapy Department, Moscow, Russia

S BavbekVKV American Hospital, Div. Medical Oncology, Istanbul, Turkey

A SellaAssaf Harofeh Centre Zerifin, Department of Oncology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Pages 93-104 | Published online: 30 Nov 2015

Cite this article
https://doi.org/10.1517/14656566.2016.1107043
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Reprints & Permissions
View PDF PDF

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Google Scholar
Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, et al. Cancer epidemiology in Central and South Eastern European countries. Croat Med J. 2011;52(4):478–487.
PubMed Web of Science ®Google Scholar
Levi F, Lucchini F, Negri E, et al. Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960. Int J Cancer. 2004;110(2):155–169.
PubMed Web of Science ®Google Scholar
Levi F, Lucchini F, Negri E, et al. Trends in cancer mortality in the European Union and accession countries, 1980–2000. Ann Oncol. 2004;15(9):1425–1431.
PubMed Web of Science ®Google Scholar
Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592.
PubMed Web of Science ®Google Scholar
Levi F, Lucchini F, Negri E, et al. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer. 2004;101(12):2843–2850.
PubMed Web of Science ®Google Scholar
Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17(suppl 8):viii15–23.
PubMedGoogle Scholar
Vrdoljak E, Ciuleanu T, Kharkevich G, et al. Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. Expert Opin Pharmacother. 2012;13(2):159–174.
PubMed Web of Science ®Google Scholar

• This paper describes the situation regarding first-line treatment for patients with metastatic renal cell carcinoma (mRCC) in the Central and Eastern European (CEE) region.

World Economic Outlook Database. International Monetary Fund. [ cited 2015 Feb 24]. Available from: http://www.imf.org/external/pubs/ft/weo/2014/02/weodata/index.aspx
Google Scholar
WHO Global Infobase. World Health Organization. 2015 [cited 2015 Jan 16]. Available from: http://apps.who.int/gho/data/node.main.78?lang=en
Google Scholar
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49–56.
PubMed Web of Science ®Google Scholar
Motzer RJ, Jonasch E, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Kidney Cancer Version 1.2016. 2016. Available from: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf
Google Scholar
Ferlay JSI, Ervik M, Dikshit R, et al. Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. GLOBOCAN 2012. [cited 2015 Jan 12]. Available from: http://globocan.iarc.fr
Google Scholar
Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 2011;104(3):399–406.
PubMed Web of Science ®Google Scholar
Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev. 2009;35(8):733–737.
PubMed Web of Science ®Google Scholar
Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000.
PubMed Web of Science ®Google Scholar
Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.
PubMed Web of Science ®Google Scholar
Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013;35(12):1955–1963.
PubMed Web of Science ®Google Scholar
Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–562.
PubMed Web of Science ®Google Scholar

•• This paper describes the Phase III data for axitinib versus sorafenib in second-line mRCC patients

Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13(10):1084–1096.
PubMed Web of Science ®Google Scholar
Buchler T, Klapka T, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Ann Oncol. 2012;23(2):395–401.
PubMed Web of Science ®Google Scholar
Buchler T, Bortlicek Z, Poprach A, et al. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis. Urol Oncol. 2014;32(5):569–575.
PubMed Web of Science ®Google Scholar
Buchler T, Pavlik T, Bortlicek Z, et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol. 2012;29(5):3321–3324.
PubMed Web of Science ®Google Scholar
Poprach A, Bortlicek Z, Buchler T, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol. 2012;29(5):3314–3320.
PubMed Web of Science ®Google Scholar
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–4265.
PubMed Web of Science ®Google Scholar

••This paper describes the Phase III data for everolimus in second-line and beyond mRCC patients

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939.
PubMed Web of Science ®Google Scholar

•• This paper describes the Phase III data for axitinib versus sorafenib in second-line mRCC patients

Ko J, Choueiri T, Rini B, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer. 2014;110(8):1917–1922.
PubMed Web of Science ®Google Scholar
Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760–767.
PubMed Web of Science ®Google Scholar
Hutson TE, Bukowski RM, Cowey CL, et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011;77(1):48–62.
PubMed Web of Science ®Google Scholar
Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272–7283.
PubMed Web of Science ®Google Scholar
Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13(2):103–111.
PubMed Web of Science ®Google Scholar
Van Geel RM, Beijnen JH, Schellens JH. Concise drug review: pazopanib and axitinib. Oncologist. 2012;17(8):1081–1089.
PubMed Web of Science ®Google Scholar
Rini BI, de La Motte Rouge T, Harzstark AL, et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer. 2013;11(2):107–114.
PubMed Web of Science ®Google Scholar
Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–3318.
PubMed Web of Science ®Google Scholar
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
PubMed Web of Science ®Google Scholar
Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8(11):975–984.
PubMed Web of Science ®Google Scholar
Poprach A, Pavlik T, Melichar B, et al. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urol Oncol. 2014;32(4):488–495.
PubMed Web of Science ®Google Scholar
Al-Marrawi MY, Rini BI, Harshman LC, et al. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol. 2013;8(3):203–209.
PubMed Web of Science ®Google Scholar
Alimohamed N, Lee J-L, Srinivas S, et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2014;12(4):e127–e31.
PubMedGoogle Scholar
Heng DY, Signorovitch J, Swallow E, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies. PloS One. 2014;9(12):e114264.
PubMed Web of Science ®Google Scholar
Iacovelli R, Cartenì G, Sternberg CN, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer. 2013;49(9):2134–2142.
PubMed Web of Science ®Google Scholar
Calvani N, Morelli F, Chiuri V, et al. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? Med Oncol. 2013;30(2):1–8.
Web of Science ®Google Scholar
Levy A, Menard J, Albiges L, et al. Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer. 2013;49(8):1898–1904.
PubMed Web of Science ®Google Scholar
Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76(2):430–434.
PubMed Web of Science ®Google Scholar
Vogelzang NJ, Hackshaw MD, Hutson TE, et al. First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology setting. Clin Genitourin Cancer. 2015;13(3):210–217.
PubMed Web of Science ®Google Scholar
Bellmunt J, Pons F, Foreshew A, et al. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clin Genitourin Cancer. 2014;12(4):262–269.
PubMed Web of Science ®Google Scholar
Wong MK, Yang H, Signorovitch JE, et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin. 2013;30(4):537–545.
PubMed Web of Science ®Google Scholar
Iacovelli R, Santoni M, Verzoni E, et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer. 2015;13(2):137–141.
PubMed Web of Science ®Google Scholar
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456.
PubMed Web of Science ®Google Scholar
Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772.
PubMed Web of Science ®Google Scholar

•• This paper describes the Phase III data for everolimus in second-line mRCC patients.

Escudier B, Szczylik C, Porta C, et al. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9(6):327–337.
PubMed Web of Science ®Google Scholar
Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010;116(23):5400–5406.
PubMed Web of Science ®Google Scholar
Escudier B, Michaelson M, Motzer R, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014;110(12):2821–2828.
PubMed Web of Science ®Google Scholar
Wong MK, Wang X, Chulikavit MJ, et al. Review of US comparative economic evidence for treatment of metastatic renal cell carcinoma after failure of first-line VEGF inhibitor therapy. Am Health Drug Benefits. 2013;6(5):275–286.
PubMedGoogle Scholar
Petrou P, Talias MA. Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):131–138.
PubMed Web of Science ®Google Scholar
Mihajlović J, Pechlivanoglou P, Sabo A, et al. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia. Clin Ther. 2013;35(12):1909–1922.
PubMed Web of Science ®Google Scholar
Casciano R, Chulikavit M, Di Lorenzo G, et al. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health. 2011;14(6):846–851.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

References

• This paper describes the situation regarding first-line treatment for patients with metastatic renal cell carcinoma (mRCC) in the Central and Eastern European (CEE) region.

•• This paper describes the Phase III data for axitinib versus sorafenib in second-line mRCC patients

••This paper describes the Phase III data for everolimus in second-line and beyond mRCC patients

•• This paper describes the Phase III data for axitinib versus sorafenib in second-line mRCC patients

•• This paper describes the Phase III data for everolimus in second-line mRCC patients.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

References

• This paper describes the situation regarding first-line treatment for patients with metastatic renal cell carcinoma (mRCC) in the Central and Eastern European (CEE) region.

•• This paper describes the Phase III data for axitinib versus sorafenib in second-line mRCC patients

••This paper describes the Phase III data for everolimus in second-line and beyond mRCC patients

•• This paper describes the Phase III data for axitinib versus sorafenib in second-line mRCC patients

•• This paper describes the Phase III data for everolimus in second-line mRCC patients.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date